I must have missed Part 1. Here it is: https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/32867249
In short, the CDC gave the AMA 5M in taxpayer dollars to come up with an IDSA Toolkit to improve care for patients with prolonged symptoms and concerns about Lyme disease.
Hopefully you can see the inherent problems with this. Once again, the wolf is being asked how to take care of the chickens. Dr. Paul Auwaerter particularly appears to speak out of both sides of his mouth.
Further, the American Medical Association (AMA) is a completely corrupt, tyrannical institution. It opposes free speech, instructs doctors to deceive, is behind persecuting doctors who think for themselves, was found GUILTY in a court of law of conspiring against chiropractic, and has completely monopolized medicine with the help of the Rockefellers.
American Medical Association Lyme Disease: A Clinician Toolkit (Part 2)
The letter below is a follow-up to the previous petition update: https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/32867249
———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: “pauwaert@jhmi.edu” <pauwaert@jhmi.edu>, “pgauwaerter@gmail.com” <pgauwaerter@gmail.com>
Cc: “cbb0@cdc.gov” <cbb0@cdc.gov>, “jjohnson@genevausa.org” <jjohnson@genevausa.org>, “theerhisamariee@gmail.com” <theerhisamariee@gmail.com>, “jaucott@jhmi.edu” <jaucott@jhmi.edu>, “jraitt1@stanford.edu” <jraitt1@stanford.edu>, “dclauw@med.umich.edu” <dclauw@med.umich.edu>, “john.leong@tufts.edu” <john.leong@tufts.edu>, “avindra.nath@nih.gov” <avindra.nath@nih.gov>, “charles.chiu@ucsf.edu” <charles.chiu@ucsf.edu>, “elliot.cowan@partnersindiagnostics.com” <elliot.cowan@partnersindiagnostics.com>, “beth.jaworski@nih.hhs.gov” <beth.jaworski@nih.hhs.gov>, “roger@lundquist.org” <roger@lundquist.org>, “rachele.hendricks.sturrup@duke.edu” <rachele.hendricks.sturrup@duke.edu>, “info@lymebiobank.org” <info@lymebiobank.org>, “lorrainejohnson@outlook.com” <lorrainejohnson@outlook.com>, “wendyadams1@gmail.com” <wendyadams1@gmail.com>, “Leith.States@hhs.gov” <Leith.States@hhs.gov>, “tindall.matt@gmail.com” <tindall.matt@gmail.com>, “stacie.hudgens@clinoutsolutions.com” <stacie.hudgens@clinoutsolutions.com>, “raymond_dattwyler@nymc.edu” <raymond_dattwyler@nymc.edu>, “timothy.sellati@globallymealliance.org” <timothy.sellati@globallymealliance.org>, “nklimas@nova.edu” <nklimas@nova.edu>, “kester@genevausa.org” <kester@genevausa.org>, “nicole@nicolemalachowski.com” <nicole@nicolemalachowski.com>, “marcom@genevausa.org” <marcom@genevausa.org>, “stephen.gluckman@pennmedicine.upenn.edu” <stephen.gluckman@pennmedicine.upenn.edu>, “epocratesMedia@athenahealth.com” <epocratesMedia@athenahealth.com>, “epocrates@athenahealth.com” <epocrates@athenahealth.com>, “achen@mathematica-mpr.com” <achen@mathematica-mpr.com>, “info@mathematica-mpr.com” <info@mathematica-mpr.com>, “pdecker@mathematica-mpr.com” <pdecker@mathematica-mpr.com>, “lwx1@cdc.gov” <lwx1@cdc.gov>, “frederick.chen@ama-assn.org” <frederick.chen@ama-assn.org>, “gmarx@cdc.gov” <gmarx@cdc.gov>, “acoyne@mathematica-mpr.com” <acoyne@mathematica-mpr.com>, “jconstantine@mathematica-mpr.com” <jconstantine@mathematica-mpr.com>, “ctrenholm@mathematica-mpr.com” <ctrenholm@mathematica-mpr.com>, “tbarnes@mathematica-mpr.com” <tbarnes@mathematica-mpr.com>, “sboudreau@mathematica-mpr.com” <sboudreau@mathematica-mpr.com>, “jdevallance@mathematica-mpr.com” <jdevallance@mathematica-mpr.com>, “sara.berg@ama-assn.org” <sara.berg@ama-assn.org>, “jack.resneck@ucsf.edu” <jack.resneck@ucsf.edu>, “jack.resneck@ama-assn.org” <jack.resneck@ama-assn.org>, “todd.unger@ama-assn.org” <todd.unger@ama-assn.org>, “jon.burkhart@ama-assn.org” <jon.burkhart@ama-assn.org>, “karen.kmetik@ama-assn.org” <karen.kmetik@ama-assn.org>, “sanjay.desai@ama-assn.org” <sanjay.desai@ama-assn.org>, “aaguilar@webmd.net” <aaguilar@webmd.net>, “DFlapan@Medscape.net” <DFlapan@Medscape.net>, “lkane@medscape.net” <lkane@medscape.net>, “gamiller@medscape.net” <gamiller@medscape.net>, “dolmos@webmd.net” <dolmos@webmd.net>, “sarah.wright@webmd.net” <sarah.wright@webmd.net>, “editor2@webmd.net” <editor2@webmd.net>, “kg@kirstengillibrand.com” <kg@kirstengillibrand.com>, “yzhang207@zju.edu.cn” <yzhang207@zju.edu.cn>, “jonathan.kanter@usdoj.gov” <jonathan.kanter@usdoj.gov>, “Antitrust.ATR@usdoj.gov” <Antitrust.ATR@usdoj.gov>, “gheltzer@mwe.com” <gheltzer@mwe.com>, “albert.sambat@usdoj.gov” <albert.sambat@usdoj.gov>, “ddutko@rustyhardin.com” <ddutko@rustyhardin.com>, “kspeer@rustyhardin.com” <kspeer@rustyhardin.com>, “katrina.rouse@usdoj.gov” <katrina.rouse@usdoj.gov>, “loppenheimer@oppenheimer-law.com” <loppenheimer@oppenheimer-law.com>
Date: 09/25/2024 9:20 AM EDT
Subject: Re: Improving Care for Patients with Prolonged Symptoms and Concerns about Lyme Disease: A Clinician Toolkit
Dr Auwaerter,
While we wait for your reply to my previous inquiry dated Sept 2nd, I would like to call attention to the following publication you coauthored with Johns Hopkins colleague Dr. Ying Zhang in 2014:
Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library – PubMed
Jie Feng, Ting Wang, Wanliang Shi, Shuo Zhang, David Sullivan, Paul G Auwaerter & Ying Zhang
https://pubmed.ncbi.nlm.nih.gov/26038747/
Excerpt:
Findings that suggest the continued presence of B. burgdorferi in some form indicate that current Lyme disease treatment may not sufficiently eliminate B. burgdorferi persisters or that the immune system fails to clear persisting organisms or bacterial debris, which may be the underlying cause for those who suffer from unresolved Lyme disease symptoms.
Recent quote from Dr. Ying Zhang: (Now with Zhejiang University School of Medicine, Hangzhou, Zhejiang, China)
“We’re dealing with a very unique situation here. The current Lyme antibiotic does not completely eradicate Borrelia bacteria. We found this dandelion phenomenon. The mower is equivalent to the antibiotics, that chopped off the top part. But because the root, the possessor, is still there, they can grow back. You need drugs targeting both parts in order to more effectively cure this persistent form of the disease.”
Dr Auwaerter,
These findings appear to be missing from your recorded interview on the AMA website: “Toolkit to Improve Care for Patients with Prolonged Symptoms and Concerns about Lyme Disease”
For the record there are seven published studies finding Dapsone effective in treating chronic Lyme disease as reported by Dr. Richard Horowitz and colleagues: 1, 2, 3, 4, 5, 6, 7
In contrast Dr. Auwaerter, you were the lead author who published the hit piece in the Lancet Infectious Diseases condemning these physicians:
Antiscience and ethical concerns associated with advocacy of Lyme disease (2011)
https://pubmed.ncbi.nlm.nih.gov/21867956/
The 5-million-dollar grant given to the AMA by the CDC for this so-called “Clinician Toolkit” would have been better spent on validating antimicrobials that cure chronic Lyme. But then again if we had the correct treatment who would opt for Pfizer’s Lyme vaccine currently in phase III clinical trials ready to roll out in 2026?
Questions:
Which CDC employee/academic stands to benefit financially (patent royalties etc.) from the soon to be released OspA Pfizer Lyme vaccine and what role have these individuals played (if any) in the ongoing collusion to deny chronic Lyme disease?
Carl Tuttle
Independent Researcher
Hudson, NH
Cc: Assistant Attorney General Jonathan Kanter, Attorney Katrina Rouse
Attorneys for the United States Antitrust Division
Assistant Attorney General Jonathan Kanter Announces Task Force on Health Care Monopolies and Collusion
https://www.justice.gov/opa/pr/assistant-attorney-general-jonathan-kanter-announces-task-force-health-care-monopolies-and
References:
1. Comparison of the Efficacy of Longer versus Shorter Pulsed High Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome with Bartonellosis and Associated Coinfections.
https://pubmed.ncbi.nlm.nih.gov/37764145/
2. Effect of dapsone alone and in combination with intracellular antibiotics against the biofilm form of B. burgdorferi.
https://pubmed.ncbi.nlm.nih.gov/32993780/
3. Efficacy of Short-Term High Dose Pulsed Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-Infections: A Report of Three Cases and Literature Review.
https://pubmed.ncbi.nlm.nih.gov/35884166/
4. Combining Double-Dose and High-Dose Pulsed Dapsone Combination Therapy for Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome and Co-Infections, Including Bartonella: A Report of 3 Cases and a Literature Review.
https://pubmed.ncbi.nlm.nih.gov/38792737/
5. Efficacy of Double-Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases and Retrospective Chart Review.
https://pubmed.ncbi.nlm.nih.gov/33105645/
6. Precision medicine: retrospective chart review and data analysis of 200 patients on dapsone combination therapy for chronic Lyme disease/post-treatment Lyme disease syndrome: part 1.
https://pubmed.ncbi.nlm.nih.gov/30863136/
7. Precision Medicine: The Role of the MSIDS Model in Defining, Diagnosing, and Treating Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome and Other Chronic Illness: Part 2.
https://pubmed.ncbi.nlm.nih.gov/30400667/
Previous inquiry to Auwaerter dated Sept 2nd:
https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/32867249
Madison Area Lyme Support Group 